- Home
- BZUN vs CHRS Comparison
BZUN vs CHRS Comparison
Compare BZUN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- CHRS
- Stock Information
- Founded
- BZUN 2007
- CHRS 2010
- Country
- BZUN China
- CHRS United States
- Employees
- BZUN N/A
- CHRS N/A
- Industry
- BZUN Catalog/Specialty Distribution
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BZUN Consumer Discretionary
- CHRS Health Care
- Exchange
- BZUN Nasdaq
- CHRS Nasdaq
- Market Cap
- BZUN 131.7M
- CHRS 84.2M
- IPO Year
- BZUN N/A
- CHRS 2014
- Fundamental
- Price
- BZUN $2.61
- CHRS $0.82
- Analyst Decision
- BZUN Buy
- CHRS Buy
- Analyst Count
- BZUN 2
- CHRS 3
- Target Price
- BZUN $3.20
- CHRS $4.68
- AVG Volume (30 Days)
- BZUN 262.6K
- CHRS 1.3M
- Earning Date
- BZUN 08-27-2025
- CHRS 08-07-2025
- Dividend Yield
- BZUN N/A
- CHRS N/A
- EPS Growth
- BZUN N/A
- CHRS N/A
- EPS
- BZUN N/A
- CHRS N/A
- Revenue
- BZUN $1,310,110,798.00
- CHRS $272,251,000.00
- Revenue This Year
- BZUN $5.27
- CHRS N/A
- Revenue Next Year
- BZUN $3.46
- CHRS $106.56
- P/E Ratio
- BZUN N/A
- CHRS $1.90
- Revenue Growth
- BZUN 6.77
- CHRS 19.87
- 52 Week Low
- BZUN $2.11
- CHRS $0.66
- 52 Week High
- BZUN $4.38
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BZUN 46.57
- CHRS 53.65
- Support Level
- BZUN $2.48
- CHRS $0.72
- Resistance Level
- BZUN $2.70
- CHRS $0.77
- Average True Range (ATR)
- BZUN 0.15
- CHRS 0.04
- MACD
- BZUN 0.00
- CHRS 0.01
- Stochastic Oscillator
- BZUN 29.18
- CHRS 91.74
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.